Breaking News

Cytovance Manufactures ARMO’s Lead Candidate

June 23, 2014

Provides drug product for Phase I trials

Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.
 
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
 
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase I dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.